Glucagon-like-1 receptor agonists and sodium/glucose cotransporter-2 inhibitors combination—are we exploiting their full potential in a real life setting?

Table 2 Differences in baseline parameters between three therapy groups

	Mean	SD	n	F ratio/Kruskal-Wallis	P value
HbA1c, %
SGLT-2i	8.09	1.07	48	6.436	0.002
GLP-1RA	8.07	1.08	76
Simultaneous	8.72	1.45	76
Total	8.32	1.26	200
FPG, mmol/L
SGLT-2i	8.75	2.17	35		0.001
GLP-1RA	9.44	2.43	55
Simultaneous	11.43	3.45	36
Total	11.17	3.23	145
BMI, kg/m2
SGLT-2i	38.18	3.60	47		0.045
GLP-1RA	38.74	4.75	70
Simultaneous	40.80	6.72	76
Total	39.41	5.49	193

BMI: Body mass index; FPG: Fasting plasma glucose; GLP-1: Glucagon-like-polypeptide-1 receptor agonist; HbA1c: Hemoglobin A1c; SD: Standard deviation; SGLT-2i: Sodium/glucose cotransporter-2 inhibitors.